Workflow
健儿消食口服液
icon
Search documents
重庆华森制药股份有限公司关于公司获得健儿消食口服液药品补充申请批准通知书暨成为药品上市许可持有人的公告
Core Viewpoint - Chongqing Huasen Pharmaceutical Co., Ltd. has received the approval notice for the supplementary application of Jian'er Xiaoshi Oral Liquid, marking the company as the holder of the drug marketing license, which is expected to enhance its product pipeline and expand its retail market presence [1][4]. Group 1: Drug Information - Jian'er Xiaoshi Oral Liquid is indicated for strengthening the spleen and stomach, regulating qi, and aiding digestion, particularly for children suffering from poor appetite and digestive issues due to irregular eating habits [2][3]. - The recommended dosage is 5-10 milliliters for children under 3 years old and 10-20 milliliters for those over 3 years, administered twice daily [2]. Group 2: Market Context - The pediatric traditional Chinese medicine market has been steadily growing, with sales reaching 18.3 billion yuan in 2024. Public hospitals account for 50.1% of sales, while retail pharmacies contribute 37% [3]. - Pediatric appetite disorder medications dominate the pediatric traditional Chinese medicine market, with Jian'er Xiaoshi Oral Liquid being a common choice due to its safety and palatable taste [3]. Group 3: Company Impact - The approval of Jian'er Xiaoshi Oral Liquid will enrich the company's product offerings and enhance its sales in the pediatric digestive field, contributing to sustainable development [4]. - The company plans to initiate marketing efforts promptly following the approval [4].
华森制药:已成为健儿消食口服液药品上市许可持有人
Core Viewpoint - Huason Pharmaceutical (002907) has successfully completed the change of drug production license holder for its product Jianer Xiaoshi Oral Liquid, marking a significant regulatory milestone for the company [1] Company Summary - The company announced on September 5 that it received the approval notice from the National Medical Products Administration regarding the supplementary application for the product [1] - The completion of the license holder change indicates that Huason Pharmaceutical is now the legal holder of the drug's marketing authorization [1]